As of June 1, 2025, Synlogic Inc (SYBX) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Synlogic Inc's Gross Margin to Peers
To better understand Synlogic Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Synlogic Inc (SYBX) | 7775.20% |
| Neoimmunetech Inc (950220.KQ) | 7775.20% |
| Evaxion Biotech A/S (EVAX) | 7775.20% |
| Scopus Biopharma Inc (SCPS) | 7775.20% |
| Galecto Inc (GLTO) | 7775.20% |
| Leap Therapeutics Inc (LPTX) | 7775.20% |
Compared to its competitors, Synlogic Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.